MedTrace Logo

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

NCT06095947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 652

Last updated 2025-09-15

No results posted yet for this study

Summary

The goal of this \[To evaluate the immunogenicity and safety of 1 - and 2-dose schedules of quadrivalent influenza vaccine (split virion) in healthy people with and without immunization history.\] is to \[aged 3-8 years\] in \[Healthy people\]. The main question\[s\] it aims to answer are: • \[To evaluate the immunogenicity of a two-dose schedule of quadrivalent influenza vaccine (quadrivalent influenza vaccine) in healthy population aged 3-8 years with or without vaccination history.\]

•\[ To evaluate whether antibody levels are different 30 days after one dose of quadrivalent influenza vaccine versus two doses of quadrivalent influenza vaccine in healthy people aged 3-8 years with or without vaccination history.\]

Conditions

  • GCP

Interventions

BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.

Sponsors & Collaborators

  • Hualan Biological Bacterin Co. Ltd.

    lead INDUSTRY

Eligibility

Min Age
3 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2023-02-06
Completion
2023-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06095947 on ClinicalTrials.gov